NCT07836270Not yet recruitingPhase 3
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Safety and Efficacy of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents (SLIMMER-YOUNG)
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 192 (estimated)
- First submitted
- 14 Sept 2026
- Start date
- 31 Oct 2026
- Primary completion date
- 8 Jun 2028
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT07836270
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 192
- From 31 Oct 2026 to the primary completion date, 8 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of receiving weight loss surgery or plan to undergo weight loss surgery during the study period (excluding acupuncture-based weight loss, liposuction, or abdominal fat removal procedures conducted more than 1 year prior to screening);
- History of using any approved or unapproved drugs for weight loss, antidiabetic drugs, long-term systemic glucocorticoids (more than 14 days), within 3 months prior to screening;
Other illness
- Known secondary obesity, including but not limited to that resulting from: hypercortisolism (e.g. Cushing's syndrome), pituitary or hypothalamic lesions, or monogenic obesity, etc.;
- Diagnosis with any type of diabetes;
- History of acute or chronic pancreatitis, history of gallbladder disease or pancreatic injury;
Other
- Pre-adolescent participants (Tanner phase 1);
Who the study is looking for
- At screening, the BMI meets the obesity criteria specified in 'WS/T586-2018 Screening for Overweight and Obesity in School-Aged Children and Adolescents', or it meets the overweight criteria and is accompanied by at least one weight-related comorbidity: hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, etc.
- Participant with body weight loss \<5% by diet and exercise for at least 3 months before screening (per self, parental/legal report).
Age in the registry: 12 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital, Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.